Companies 0 See All
Hedge Funds 0 See All
Insiders 0 See All
Institutional Investors 0 See All
Click here to see all results for
Home > Insider Trading > Filing (0001144204-14-006637)

Filing Details

Accession Number:
0001144204-14-006637
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-02-06 18:02:47
Reporting Period:
2014-02-04
Filing Date:
2014-02-06
Accepted Time:
2014-02-06 18:02:47
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1138776 Medgenics Inc. MDGN Biological Products, (No Disgnostic Substances) (2836) 980217544
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1516544 Andrew Pearlman C/O Medgenics, Inc.
435 Devon Park Drive Bldg 700
Wayne PA 19087		 Yes No No No
Reported Non-Derivative Transactions
Show Other Fields >>
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-02-04 16,800 $2.49 57,362 No 4 M Direct
Common Stock Acquisiton 2014-02-04 3,200 $3.14 60,562 No 4 M Direct
Common Stock Disposition 2014-02-04 20,000 $8.00 40,562 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Show Other Fields >>
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Option Award (right to buy) Disposition 2014-02-04 16,800 $0.00 16,800 $2.49
Common Stock Option Award (right to buy) Disposition 2014-02-04 3,200 $0.00 3,200 $3.14
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
92,006 2014-09-13 No 4 M Direct
45,800 2014-09-13 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 94 Indirect By Spouse
Common Stock 1,719 Indirect By ADP Holdings LLC
Footnotes
  1. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2013.
  2. The option award became fully exercisable on September 13, 2013 in accordance with the terms of the reporting person's separation agreement entered into upon his resignation as the issuer's President and Chief Executive Officer.